Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer

NCT06493019 is registered in ClinicalTrials.gov with Dustin Deming as lead sponsor.

NCT NCT06493019
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06493019 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer
Lead sponsor
Dustin Deming
Phase
Phase 2
Overall status
Recruiting
Start date
September 30, 2024
Completion date
April 14, 2029
Enrollment
23 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

anal cancer